【摘要】：目的觀察非小細(xì)胞肺癌腫瘤組織、癌旁正常肺組織及淋巴結(jié)中VEGF-C、VEGFR-3及BMP-9的表達(dá)情況,并結(jié)合臨床病理特征分析其表達(dá)在非小細(xì)胞肺癌原發(fā)病灶進(jìn)展及淋巴結(jié)轉(zhuǎn)移等生物學(xué)行為中的意義。方法選擇行肺葉切除+淋巴結(jié)清掃術(shù)、術(shù)后我院病理證實(shí)的NSCLC患者的組織標(biāo)本為研究對(duì)象,并收集患者的完整病例資料�？偣彩占饺虢M患者的51例腫瘤組織、51例對(duì)應(yīng)的癌旁正常肺組織、43枚癌轉(zhuǎn)移淋巴結(jié)(其中8例N1期患者:N1期淋巴結(jié)15枚;16例N2期患者:N1期淋巴結(jié)9枚,N2期淋巴結(jié)19枚)及51枚非轉(zhuǎn)移性淋巴結(jié)(患側(cè)10組或11組)。采用免疫組織化學(xué)法分別檢測(cè)51例NSCLC癌組織及51例正常肺組織中VEGF-C、VEGFR-3和BMP-9的表達(dá),分別檢測(cè)43枚癌轉(zhuǎn)移陽(yáng)性淋巴結(jié)及51枚非轉(zhuǎn)移淋巴結(jié)中VEGF-C、VEGFR-3的表達(dá)。結(jié)合陽(yáng)性細(xì)胞百分率和細(xì)胞總體染色強(qiáng)度對(duì)組織染色結(jié)果進(jìn)行半定量積分分析,計(jì)算出對(duì)應(yīng)的陽(yáng)性表達(dá)率,最后經(jīng)統(tǒng)計(jì)發(fā)現(xiàn)VEGF-C、VEGFR-3和BMP-9在不同性別、年齡、吸煙史、腫瘤組織類(lèi)型、腫瘤T分期、淋巴結(jié)轉(zhuǎn)移情況、淋巴結(jié)N分期及轉(zhuǎn)移淋巴結(jié)數(shù)目等亞組的陽(yáng)性表達(dá)率,并分析VEGF-C、VEGFR-3和BMP-9的表達(dá)在亞組間的統(tǒng)計(jì)學(xué)關(guān)系及內(nèi)在聯(lián)系。結(jié)果1.VEGF-C陽(yáng)性表達(dá)為棕黃色,主要位于癌細(xì)胞胞質(zhì)內(nèi)。N0期亞組、N1期亞組、N2期亞組中腫瘤組織VEGF-C表達(dá)率均顯著高于對(duì)應(yīng)的癌旁正常肺組織(P0.05)。腫瘤組織中VEGF-C的表達(dá)在有淋巴結(jié)轉(zhuǎn)移組高于無(wú)淋巴結(jié)轉(zhuǎn)移組,差異有非常顯著統(tǒng)計(jì)學(xué)意義(P0.01)。正常肺組織中VEGF-C的表達(dá)在無(wú)淋巴結(jié)轉(zhuǎn)移組高于有淋巴結(jié)轉(zhuǎn)移組,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。癌組織VEGF-C的表達(dá)在N2期亞組高于N1期亞組,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。癌組織VEGF-C的表達(dá)在N2期亞組高于N0期亞組,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。癌組織VEGF-C的表達(dá)在淋巴結(jié)轉(zhuǎn)移數(shù)目≥3(LN+)亞組高于0(LN+)亞組,差異有非常顯著統(tǒng)計(jì)學(xué)意義(P0.01)。癌組織VEGF-C的表達(dá)在淋巴結(jié)轉(zhuǎn)移數(shù)目≥3(LN+)亞組高于1~2(LN+)亞組,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。正常肺組織VEGF-C的表達(dá)在淋巴結(jié)轉(zhuǎn)移數(shù)目0(LN+)亞組高于≥3(LN+)亞組,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。正常肺組織VEGF-C的表達(dá)在淋巴結(jié)轉(zhuǎn)移數(shù)目1~2(LN+)亞組高于≥3(LN+)亞組,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。在無(wú)淋巴結(jié)轉(zhuǎn)移的腫瘤組織中,VEGF-C的表達(dá)在T3-4期亞組高于T2期亞組,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。在無(wú)淋巴結(jié)轉(zhuǎn)移的正常肺組織中,VEGF-C的表達(dá)在T3-4期亞組高于T2期亞組,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。2.VEGFR-3陽(yáng)性表達(dá)為棕黃色,主要位于淋巴管內(nèi)皮細(xì)胞和部分癌細(xì)胞胞漿。N0期亞組、N1期亞組、N2期亞組中腫瘤組織VEGFR-3表達(dá)率均顯著高于對(duì)應(yīng)的癌旁正常肺組織(P0.05)。腫瘤組織中VEGFR-3的表達(dá)在有淋巴結(jié)轉(zhuǎn)移組高于無(wú)淋巴結(jié)轉(zhuǎn)移組,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。正常肺組織中VEGFR-3的表達(dá)在有淋巴結(jié)轉(zhuǎn)移組高于無(wú)淋巴結(jié)轉(zhuǎn)移組,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。癌組織VEGFR-3的表達(dá)在N2期亞組高于N1期亞組,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。癌組織VEGFR-3的表達(dá)在N2期亞組高于N0期亞組,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。正常肺組織VEGFR-3的表達(dá)在N2期亞組高于N1期亞組,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。正常肺組織VEGFR-3的表達(dá)在N2期亞組高于N0期亞組,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。癌組織VEGFR-3的表達(dá)在淋巴結(jié)轉(zhuǎn)移數(shù)目≥3(LN+)亞組高于0(LN+)亞組,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。正常肺組織VEGFR-3的表達(dá)在淋巴結(jié)轉(zhuǎn)移數(shù)目≥3(LN+)亞組高于0(LN+)亞組,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。在無(wú)淋巴結(jié)轉(zhuǎn)移的NSCLC正常肺組織中,VEGFR-3的表達(dá)在T3-4期亞組高于T1期亞組,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。在無(wú)淋巴結(jié)轉(zhuǎn)移的NSCLC正常肺組織中,VEGF-C的表達(dá)在T3-4期亞組高于T2期亞組,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。3.BMP-9陽(yáng)性表達(dá)為棕黃色,主要位于正常癌旁肺組織細(xì)胞及部分癌細(xì)胞、巨噬細(xì)胞胞質(zhì)。N0期亞組、N2期亞組的癌旁正常肺組織BMP-9表達(dá)顯著高于對(duì)應(yīng)的腫瘤組織(P0.05)。N1期亞組的腫瘤組織BMP-9表達(dá)顯著高于對(duì)應(yīng)的癌旁正常肺組織(P0.05)。腫瘤組織中BMP-9的表達(dá)在有淋巴結(jié)轉(zhuǎn)移組高于無(wú)淋巴結(jié)轉(zhuǎn)移組,差異有非常顯著統(tǒng)計(jì)學(xué)意義(P0.01)。正常肺組織中BMP-9的表達(dá)在有淋巴結(jié)轉(zhuǎn)移組高于無(wú)淋巴結(jié)轉(zhuǎn)移組,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。癌組織BMP-9的表達(dá)在N1期亞組高于N0期亞組,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.01)。癌組織BMP-9的表達(dá)在N1期亞組高于N2期亞組,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。癌組織BMP-9的表達(dá)在N2期亞組高于N0期亞組,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。正常肺組織BMP-9的表達(dá)在N2期亞組高于N1期亞組,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。正常肺組織BMP-9的表達(dá)在N2期亞組高于N0期亞組,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.01)。癌組織BMP-9的表達(dá)在淋巴結(jié)轉(zhuǎn)移數(shù)目1~2(LN+)亞組高于0(LN+)亞組,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。癌組織BMP-9的表達(dá)在淋巴結(jié)轉(zhuǎn)移數(shù)目≥3(LN+)亞組高于0(LN+)亞組,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。正常肺組織BMP-9的表達(dá)在淋巴結(jié)轉(zhuǎn)移數(shù)目≥3(LN+)亞組高于0(LN+)亞組,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。在有淋巴結(jié)轉(zhuǎn)移的NSCLC腫瘤組織中,BMP-9的表達(dá)在T3-4期亞組高于T1期亞組,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。在有淋巴結(jié)轉(zhuǎn)移的NSCLC腫瘤組織中,BMP-9的表達(dá)在T3-4期亞組高于T2期亞組,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。在有淋巴結(jié)轉(zhuǎn)移的NSCLC正常肺組織中,BMP-9的表達(dá)在T3-4期亞組高于T1期亞組,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。在有淋巴結(jié)轉(zhuǎn)移的NSCLC正常肺組織中,BMP-9的表達(dá)在T3-4期亞組高于T2期亞組,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。在無(wú)淋巴結(jié)轉(zhuǎn)移的NSCLC腫瘤組織中,BMP-9的表達(dá)在T3-4期亞組高于T2期亞組,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。4.腫瘤組織及癌旁組織中VEGF-C、VEGFR-3、BMP-9的表達(dá)在各個(gè)性別、年齡、吸煙史、腫瘤組織類(lèi)型亞組之間均無(wú)顯著差異(P0.05)。5.淋巴結(jié)VEGF-C的表達(dá)在N1期亞組較N0期亞組升高,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.05);淋巴結(jié)VEGFR-3的表達(dá)在N1期亞組較N0期亞組升高,差異有非常顯著統(tǒng)計(jì)學(xué)意義(P0.01)。淋巴結(jié)VEGF-C的表達(dá)在N2期亞組較N1期亞組升高,差異有非常顯著統(tǒng)計(jì)學(xué)意義(P0.01);淋巴結(jié)VEGFR-3的表達(dá)在N2期亞組較N1期亞組升高,差異有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。淋巴結(jié)VEGF-C的表達(dá)在N2期亞組較N0期亞組升高,差異有非常顯著統(tǒng)計(jì)學(xué)意義(P0.01);淋巴結(jié)VEGFR-3的表達(dá)在N2期亞組較N0期亞組升高,差異有非常顯著統(tǒng)計(jì)學(xué)意義(P0.01)。6.VEGF-C、VEGFR-3在所有入組的51例NSCLC癌組織中的表達(dá)存在明顯的正相關(guān)(r=0.346,P0.05);VEGF-C、VEGFR-3在有淋巴結(jié)轉(zhuǎn)移的24例NSCLC癌組織中的表達(dá)存在明顯的正相關(guān)(r=0.755,P0.01)。VEGF-C、VEGFR-3在所有入組的43例NSCLC轉(zhuǎn)移淋巴結(jié)中的表達(dá)亦存在明顯的正相關(guān)(r=0.436,P0.01);VEGF-C、VEGFR-3在23例N1期NSCLC淋巴結(jié)中的表達(dá)亦存在明顯的正相關(guān)(r=0.874,P0.01);VEGF-C、VEGFR-3在44例N2期NSCLC淋巴結(jié)中的表達(dá)亦存在明顯的正相關(guān)(r=0.702,P0.01)。結(jié)論1.VEGF-C、VEGFR-3在不同N分期的NSCLC癌組織中的表達(dá)均較癌旁組織明顯增高。VEGF-C、VEGFR-3在NSCLC腫瘤組織中的表達(dá)均與淋巴結(jié)轉(zhuǎn)移有顯著的相關(guān)性。VEGF-C、VEGFR-3在NSCLC正常肺組織中的表達(dá)均與淋巴結(jié)轉(zhuǎn)移有顯著的相關(guān)性。NSCLC癌組織VEGF-C、VEGFR-3的表達(dá)在N2期亞組較N1期亞組、N0期亞組均顯著升高。NSCLC正常肺組織VEGFR-3的表達(dá)在N2期亞組較N1期亞組、N0期亞組均顯著升高。癌組織VEGF-C、VEGFR-3的表達(dá)在淋巴結(jié)轉(zhuǎn)移數(shù)目≥3(LN+)亞組較0(LN+)亞組均顯著升高。癌組織VEGF-C的表達(dá)在淋巴結(jié)轉(zhuǎn)移數(shù)目≥3(LN+)亞組較1~2(LN+)亞組顯著升高。NSCLC正常肺組織VEGF-C、VEGFR-3的表達(dá)在淋巴結(jié)轉(zhuǎn)移數(shù)目≥3(LN+)亞組較0(LN+)亞組均顯著升高。NSCLC正常肺組織VEGF-C的表達(dá)在淋巴結(jié)轉(zhuǎn)移數(shù)目≥3(LN+)亞組較1~2(LN+)亞組顯著升高。在無(wú)淋巴結(jié)轉(zhuǎn)移的腫瘤組織及正常肺組織中,VEGF-C在T3-4期亞組的表達(dá)顯著高于T2期亞組。在無(wú)淋巴結(jié)轉(zhuǎn)移的NSCLC正常肺組織中,VEGFR-3的表達(dá)在T3-4期亞組高于T1期亞組、T2期亞組。VEGF-C、VEGFR-3在有淋巴結(jié)轉(zhuǎn)移的腫瘤組織中的表達(dá)具有明顯正相關(guān)性,且兩者在轉(zhuǎn)移淋巴結(jié)中的表達(dá)亦具有明顯正相關(guān)性。VEGF-C、VEGFR-3在淋巴結(jié)中的表達(dá)與淋巴結(jié)N分期顯著相關(guān)。我們觀察到在NSCLC腫瘤組織及轉(zhuǎn)移淋巴結(jié)中VEGF-C、VEGFR-3的表達(dá)上調(diào)與既往文獻(xiàn)報(bào)告中其他惡性腫瘤組織的兩者表達(dá)情況類(lèi)似,VEGF-C、VEGFR-3可能參與NSCLC原發(fā)癌灶局部侵襲、淋巴管生成及淋巴結(jié)轉(zhuǎn)移。2.BMP-9在N0期及N2期的NSCLC癌組織中的表達(dá)較癌旁組織顯著降低,而在N1期癌組織中的表達(dá)較癌旁組織顯著升高。BMP-9在NSCLC腫瘤組織及正常肺組織中的表達(dá)與淋巴結(jié)轉(zhuǎn)移均存在顯著的相關(guān)性。NSCLC腫瘤組織BMP-9的表達(dá)在N1期亞組較N0期亞組、N2期亞組顯著升高,在N2期亞組較N0期亞組亦顯著升高。腫瘤組織BMP-9的表達(dá)在淋巴結(jié)轉(zhuǎn)移數(shù)目≥3(LN+)亞組較0(LN+)亞組顯著升高,在淋巴結(jié)轉(zhuǎn)移數(shù)目為1~2(LN+)亞組較0(LN+)亞組亦顯著升高。正常肺組織BMP-9的表達(dá)在N2期亞組較N1期亞組、N0期亞組均顯著升高。正常肺組織BMP-9的表達(dá)在淋巴結(jié)轉(zhuǎn)移數(shù)目≥3(LN+)亞組較0(LN+)亞組顯著升高。在有淋巴結(jié)轉(zhuǎn)移的腫瘤組織中,BMP-9在T3-4期亞組的表達(dá)顯著高于T2期亞組、T1期亞組。在有淋巴結(jié)轉(zhuǎn)移的正常肺組織中,BMP-9在T3-4期亞組的表達(dá)顯著高于T2期亞組、T1期亞組。在無(wú)淋巴結(jié)轉(zhuǎn)移的腫瘤組織中,BMP-9在T3-4期亞組的表達(dá)顯著高于T2期亞組。我們觀察到在無(wú)淋巴結(jié)轉(zhuǎn)移的NSCLC腫瘤組織BMP-9的表達(dá)相對(duì)癌旁組織下降,而在有淋巴結(jié)轉(zhuǎn)移的NSCLC腫瘤組織及正常肺組織中BMP-9表達(dá)相對(duì)升高的現(xiàn)象與既往文獻(xiàn)報(bào)告中其他惡性腫瘤組織的BMP-9表達(dá)情況類(lèi)似,BMP-9可能與NSCLC原發(fā)癌灶局部侵襲、腫瘤淋巴管生成及淋巴結(jié)轉(zhuǎn)移相關(guān)。3.NSCLC腫瘤組織及癌旁組織中VEGF-C、VEGFR-3、BMP-9的表達(dá)均與患者性別、年齡、吸煙史、腫瘤組織類(lèi)型無(wú)相關(guān)性。4.VEGF-C、VEGFR-3在NSCLC腫瘤組織、癌旁正常肺組織及淋巴結(jié)中的表達(dá)與NSCLC淋巴管生成、淋巴結(jié)轉(zhuǎn)移具有一定正相關(guān)性,而B(niǎo)MP-9在NSCLC腫瘤組織、癌旁組織中的表達(dá)與NSCLC淋巴管生成、淋巴結(jié)轉(zhuǎn)移具有一定負(fù)相關(guān)性。以上結(jié)論有益于進(jìn)一步研究NSCLC轉(zhuǎn)移的正負(fù)靶向調(diào)控治療。
[Abstract]:Objective To observe the expression of VEGF-C, VEGFR-3 and BMP-9 in the tumor tissue of non-small cell lung cancer, normal lung tissue and lymph nodes adjacent to the carcinoma, and to analyze the significance of its expression in the biological behavior of primary lesion and lymph node metastasis of non-small cell lung cancer combined with clinicopathological features. Methods pulmonary lobectomy plus lymph node dissection was performed. A total of 51 NSCLC patients were collected and collected in our hospital. A total of 51 tumor tissues were collected, 51 normal paracancerous lung tissues and 43 metastatic lymph nodes (8 N1 patients, 15 N1 lymph nodes, 16 N2 patients, 9 lymph nodes in N1 phase, N2 phase drenching). 19 and 51 non metastatic lymph nodes (10 or 11 sides). The expression of VEGF-C, VEGFR-3 and BMP-9 in 51 cases of NSCLC and 51 normal lung tissues were detected by immunohistochemistry. The expression of VEGF-C and VEGFR-3 in 43 positive lymph nodes and 51 non metastatic lymph nodes were detected respectively. The results of tissue staining were semi quantified by rate and cell overall staining intensity, and the positive expression rate was calculated. Finally, VEGF-C, VEGFR-3 and BMP-9 were found in different sex, age, smoking history, tumor tissue type, tumor T staging, lymph node metastasis, lymph node N staging and the number of metastatic lymph nodes. The expression rate of VEGF-C, VEGFR-3 and BMP-9 expressed in the subgroup. Results the positive expression of 1.VEGF-C was brown, mainly located in the.N0 phase subgroup, N1 phase subgroup, and N2 phase subgroup, and the expression of VEGF-C in the N2 phase subgroup was significantly higher than that of the corresponding normal lung tissue (P0.05). The expression of VEGF-C in the lymph node metastasis group was higher than that in the non lymph node metastasis group. The difference was significant (P0.01). The expression of VEGF-C in the normal lung tissue was higher than that in the lymph node metastasis group, and the difference was statistically significant (P0.05). The expression of VEGF-C in the cancer group was higher than the N1 subgroup in the N2 phase subgroup, and the difference was different. There was significant statistical significance (P0.05). The expression of VEGF-C in the carcinoma tissue was higher than that of the N0 subgroup (P0.05) in the N2 phase subgroup (P0.05). The expression of VEGF-C in the carcinoma tissue was higher than the 0 (LN+) subgroup of the lymph node metastases (LN+) subgroup, and the difference was statistically significant (P0.01). The expression of VEGF-C in the carcinoma tissue was in the number of lymph node metastases. The subgroup over 3 (LN+) was higher than that of the 1~2 (LN+) subgroup, the difference was significant (P0.05). The expression of VEGF-C in the normal lung tissue was higher than that of the subgroup of 0 (LN+) of lymph node metastasis (LN+), and the difference was statistically significant (P0.05). The expression of VEGF-C in normal lung tissue was higher than that in the 1~2 (LN+) subgroup of lymph node metastases (LN+) subgroup (LN+)). There was significant statistical significance (P0.05). In the tumor tissue without lymph node metastasis, the expression of VEGF-C in T3-4 phase subgroup was higher than that in T2 subgroup (P0.05). In normal lung tissue without lymph node metastasis, the expression of VEGF-C in T3-4 phase subgroup was higher than that of T2 phase subgroup (P0.05).2.VEGFR-3 (P0.05).2.VEGFR-3. The positive expression was brown yellow, mainly located in the lymphovascular endothelial cells and part of the cytoplasm.N0 subgroup of cancer cells, the N1 phase subgroup and the N2 phase subgroup were significantly higher than that of the corresponding normal lung tissue (P0.05). The expression of VEGFR-3 in the tumor tissue was higher than that in the non lymph node group, and the difference was significantly higher than that in the non lymph node group. Statistical significance (P0.05). The expression of VEGFR-3 in the normal lung tissue was higher than that in the non lymph node metastasis group, and the difference was statistically significant (P0.05). The expression of VEGFR-3 in the carcinoma tissue was higher than that in the N1 subgroup (P0.05). The expression of VEGFR-3 in the cancer tissue was higher than the N0 phase in the N2 subgroup. The difference was significant (P0.05). The expression of VEGFR-3 in normal lung tissue was higher than that in phase N1 subgroup (P0.05). The expression of VEGFR-3 in normal lung tissue was higher than that of N0 phase subgroup (P0.05) in N2 phase subgroup (P0.05). The expression of VEGFR-3 in cancer tissue was more than 3 (L) in lymph node metastasis (L). N+) the subgroup was higher than the 0 (LN+) subgroup, and the difference was significant (P0.05). The expression of VEGFR-3 in normal lung tissue was higher than that of the 0 (LN+) subgroup with the number of lymph node metastasis (LN+), and the difference was statistically significant (P0.05). The expression of VEGFR-3 in the T3-4 phase subgroup was higher than that in the T1 phase group in the normal lung tissue without lymph node metastasis. There was significant statistical significance (P0.05). In the normal lung tissue of NSCLC without lymph node metastasis, the expression of VEGF-C in the T3-4 subgroup was higher than that of the T2 phase subgroup. The difference was statistically significant (P0.05) the positive expression of.3.BMP-9 was brown, mainly located in the normal paracancerous lung tissue cells and some cancer cells, the.N0 phase subgroup of macrophage cytoplasm, and the N2 subgroup The expression of BMP-9 in the normal lung tissue adjacent to the carcinoma was significantly higher than that of the corresponding tumor tissue (P0.05).N1 phase subgroup, and the expression of BMP-9 was significantly higher than that of the corresponding normal lung tissue (P0.05). The expression of BMP-9 in the tumor tissue was higher than that in the non lymph node group (P0.01). The difference was significant (P0.01). The expression of BMP-9 in the lymph node metastasis group was higher than that in the non lymph node metastasis group, and the difference was statistically significant (P0.05). The expression of BMP-9 in the carcinoma tissue was higher than that in the N0 phase group (P0.01). The expression of BMP-9 in the cancer tissue was higher than the N2 group in the N1 phase subgroup, and the difference was significant statistically significant (P0.05). The expression of BMP-9 in the N2 phase was higher than that of the N0 subgroup (P0.05). The expression of BMP-9 in the normal lung tissue was higher than that in the N1 subgroup (P0.05). The expression of BMP-9 in the normal lung tissue was higher than that in the N0 phase group (P0.01). The difference was statistically significant (P0.01). The expression of BMP-9 in the lymph node metastasis number 1~2 (LN+) subgroup was higher than that of the 0 (LN+) subgroup, the difference was significant (P0.05). The expression of BMP-9 in the carcinoma tissue was higher than the 0 (LN+) subgroup of the lymph node metastasis number (LN+) subgroup, and the difference was significant (P0.05). The expression of BMP-9 in normal lung tissue was more than 3 (LN+) subgroup of lymph node metastasis. The difference was significant (P0.05) in the group of 0 (LN+) subgroup (P0.05). In the NSCLC tumor with lymph node metastasis, the expression of BMP-9 was higher than that of the T1 subgroup (P0.05). In NSCLC tumor tissues with lymph node metastasis, the expression of BMP-9 in the T3-4 phase subgroup was higher than that in the T2 phase group, and the difference was significant. P0.05. In NSCLC normal lung tissues with lymph node metastasis, the expression of BMP-9 in the T3-4 subgroup was higher than that in the T1 phase subgroup, and the difference was statistically significant (P0.05). In the normal lung tissue with lymph node metastasis, the expression of BMP-9 in the T3-4 phase group was higher than the T2 phase subgroup, and the difference was statistically significant (P0.05). In the non lymphatic group, the difference was significant (P0.05). In NSCLC tumor metastases, the expression of BMP-9 in T3-4 phase subgroup was higher than that of phase T2 subgroup. The difference was significant (P0.05).4. tumor tissue and the expression of VEGF-C, VEGFR-3, and BMP-9 in.4. tumor tissues and adjacent tissues, and there was no significant difference between the sex, age, smoking history and tumor tissue subgroup (P0.05).5. lymph node VEGF-C. The difference was significant (P0.05) in the group N1 subgroup compared with the N0 subgroup (P0.05); the expression of VEGFR-3 in the lymph node was higher than that in the N0 phase subgroup (P0.01). The expression of VEGF-C in lymph node was higher in the N2 group than in the N1 phase subgroup, and the difference was statistically significant (P0.01); lymph node VEGFR-3. The expression in phase N2 subgroup was higher than that in N1 subgroup (P0.05). The expression of VEGF-C in lymph node was higher than that in N0 phase subgroup, and the difference was statistically significant (P0.01); the expression of VEGFR-3 in lymph node was higher in the N2 phase than in the N0 phase subgroup, and the difference was statistically significant (P0.01).6.VEGF-C. There was a significant positive correlation (r=0.346, P0.05) in the expression of R-3 in all 51 cases of NSCLC cancer, and VEGF-C, VEGFR-3 had a significant positive correlation (r=0.755, P0.01).VEGF-C in 24 cases of NSCLC carcinoma with lymph node metastasis, and VEGFR-3 was also positively correlated with the expression of the 43 cases of NSCLC metastatic lymph nodes. =0.436, P0.01); VEGF-C, VEGFR-3 was also positively correlated (r=0.874, P0.01) in 23 N1 phase NSCLC lymph nodes. VEGF-C, VEGFR-3 was also positively correlated in the 44 N2 NSCLC lymph nodes. The expression of VEGFR-3 in NSCLC tumor tissues was significantly correlated with lymph node metastasis, and the expression of VEGFR-3 in NSCLC normal lung tissues was significantly correlated with lymph node metastasis of.NSCLC cancer tissue VEGF-C, VEGFR-3 expression in the N2 phase subgroup was higher than that in the N1 phase group, and the N0 phase subgroup significantly increased the normal lung group. The expression of VEGFR-3 was significantly higher in the N2 subgroup than in the N1 phase subgroup and in the N0 phase subgroup. The expression of VEGF-C and VEGFR-3 in the carcinoma tissue was significantly higher in the number of lymph node metastases (LN+) than in the 0 (LN+) subgroup. The expression of VEGF-C in the carcinoma tissue was significantly higher in the number of lymph node metastases (LN+) than in the 1~2 (LN+) subgroup. The expression of GFR-3 in the group of lymph node metastasis more than 3 (LN+) was significantly higher than that of the 0 (LN+) subgroup. The expression of VEGF-C in the normal lung tissue of.NSCLC was significantly higher than that in the subgroup of 1~2 (LN+) with the number of lymph node metastases more than 3 (LN+). In the tumor tissue without lymph node metastasis and in the normal lung group, the expression of VEGF-C in the T3-4 phase subgroup was significantly higher than that of the T2 phase subgroup. In NSCLC normal lung tissues without lymph node metastasis, the expression of VEGFR-3 in the T3-4 phase subgroup was higher than that in the T1 subgroup. The T2 phase subgroup.VEGF-C, VEGFR-3 had a positive correlation in the tumor tissue with lymph node metastasis, and the expression of the two in the metastatic lymph nodes also had a significant positive correlation of.VEGF-C and VEGFR-3 in the lymph nodes. The expression of VEGF-C was significantly correlated with the N staging of lymph nodes. We observed that the expression of VEGF-C in NSCLC tumor tissues and metastatic lymph nodes was similar to those of other malignant tumor tissues in previous reports. VEGF-C, VEGFR-3 may be involved in the local invasion, lymphangiogenesis and lymph node metastasis of the primary cancer of the NSCLC. The expression of NSCLC in the N0 and N2 phase was significantly lower than that in the paracancerous tissue, while the expression in the N1 carcinoma tissue was significantly higher than that of the paracancerous tissue. The expression of.BMP-9 in the NSCLC tumor tissue and the normal lung tissue was significantly correlated with the lymph node metastasis. The expression of BMP-9 in the.NSCLC tumor tissue was compared with the N0 phase subgroup in the N1 phase group and the N2 phase. The subgroup was significantly higher in the subgroup N2 than the N0 subgroup. The expression of BMP-9 in the tumor tissue was significantly higher than the 0 (LN+) subgroup with the number of lymph node metastases (LN+), and the number of lymph node metastasis was 1~2 (LN+) subgroup as compared with the 0 (LN+) subgroup. The expression of BMP-9 in the normal lung tissue was in the N2 phase subgroup than the N1 subgroup and the N0 phase subgroup The expression of BMP-9 in normal lung tissue was significantly higher in the subgroup of lymph node metastasis (LN+) than in the subgroup of 0 (LN+). In the tumor tissue with lymph node metastasis, the expression of BMP-9 in the T3-4 phase subgroup was significantly higher than that of the T2 phase subgroup and the T1 phase subgroup. In the normal lung tissue with lymph node metastasis, the expression of BMP-9 in the T3-4 subgroup was significant. The expression of BMP-9 in the T3-4 phase subgroup was significantly higher than that in the T2 phase subgroup in the non lymph node metastases. We observed that the expression of BMP-9 in the NSCLC tumor tissue without lymph node metastasis was lower than that of the para cancerous tissue in the NSCLC tumor tissue without lymph node metastasis, and the BMP-9 expression in the NSCLC tumor tissue and normal lung tissues with lymph node metastasis was observed. Similar to the BMP-9 expression in other malignant tumor tissues reported previously, BMP-9 may be associated with NSCLC primary cancer site.
【學(xué)位授予單位】：重慶醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類(lèi)號(hào)】：R734.2

【參考文獻(xiàn)】

相關(guān)期刊論文 前6條

1 李少雷;陳晉峰;鄭慶鋒;吳楠;閻石;王洋;張建芝;楊躍;;Endostatin VEGF-C和VEGFR-3在非小細(xì)胞肺癌及其淋巴結(jié)組織中的表達(dá)與意義[J];中國(guó)腫瘤臨床;2011年24期

2 ;Expression of vascular endothelial growth factor-C and angiogenesis in esophageal squamous cell carcinoma[J];World Journal of Gastroenterology;2006年28期

3 曹桂明;楊梅;;VEGF-C和VEGFR-3對(duì)乳腺癌淋巴管生成和淋巴結(jié)轉(zhuǎn)移的影響[J];中國(guó)腫瘤臨床;2006年06期

4 李凱;陶京;王春友;;胰腺癌淋巴管生成與血管內(nèi)皮生長(zhǎng)因子C的關(guān)系[J];中華實(shí)驗(yàn)外科雜志;2006年01期

5 姜漢國(guó),高嵋,唐慰萍,李飛虹,蔡瓊珍;VEGF、VEGF-C和VEGF-D在甲狀腺乳頭狀癌組織中的表達(dá)及意義[J];癌癥;2005年09期

6 許良中，，楊文濤;免疫組織化學(xué)反應(yīng)結(jié)果的判斷標(biāo)準(zhǔn)[J];中國(guó)癌癥雜志;1996年04期

本文編號(hào)：2149736